Published in Gene Therapy Weekly, February 23rd, 2006
"Insights into the molecular basis of hormone-refractory prostate cancer have principally relied on human prostate cancer cell lines, all of which were derived from patients who had already failed hormonal therapy."
"Recent progress in developing genetically engineered mouse prostate cancer models provides an opportunity to isolate novel cell lines front animals never exposed to hormone ablation, avoiding any potential bias conferred by the selective pressure of the castrate environment," wrote P.A. Watson and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.